Male reproductive health platform Posterity Health has secured $13 million in Series A funding to expand its comprehensive care services nationwide. The round was led by Georgetown Equity Partners, with participation from existing investors FCA Venture Partners, Distributed Ventures, and WVV. Notable new investors include women’s health fund SteelSky Ventures, Scrub Capital, and other digital health leaders.
“I’ve committed my career to male reproductive health because it remains one of the most underserved and poorly understood areas within healthcare,” said Pam Pure, the CEO and Co-Founder of Posterity Health. “This funding gives us the opportunity to serve more men and their families, and it also demonstrates that the tide is turning and that men are starting to take a more active role in their own health. I’m proud to be part of that change.”
The company’s platform addresses several critical gaps in male reproductive healthcare, combining telehealth services, at-home diagnostics, and in-person care. Traditional care models often delay male evaluation for nearly two years, leading to unnecessary treatments and higher costs. With only 250 fellowship-trained reproductive urologists nationwide, access to specialists remains a significant challenge.
“We are proud to partner with Posterity Health as they transform male reproductive care, improving outcomes for both men and women,” said Maria Toler, Founding & Managing Partner at SteelSky Ventures. “Women’s health doesn’t exist in a silo — male reproductive health is an essential part of the equation. By addressing male fertility earlier, we can reduce unnecessary, invasive treatments for women and help couples navigate the fertility journey more efficiently — saving time, money, and stress while improving success rates for couples trying to conceive.”
In a significant development for the company, Dr. William Schoolcraft, a global pioneer in fertility treatment, has joined Posterity Health as a Strategic Advisor. Dr. Schoolcraft will lead efforts to educate clinicians and the public on the importance of early male fertility evaluation.
“Treating the male partner will avoid unnecessary female care, improve sperm quality, and even identify underlying health conditions like testicular cancer,” said Dr. Schoolcraft. “I am excited about the opportunity to team with Posterity Health to shift the burden of care from the female, provide a more equitable fertility process, and improve IVF success rates.”
The platform also addresses the challenges of hormone management, particularly the overprescription and mismanagement of testosterone therapy, which can negatively impact fertility. Additionally, Posterity Health’s data-driven tools help detect potential underlying health risks early, as male infertility has been linked to conditions including testicular cancer, high blood pressure, and obesity.
“We see powerful benefits to females who are given the opportunity to manage their reproductive journey from pre-conception to menopause, and we believe that males deserve and are seeking out the same proactive care,” said Rebecca Mitchell, M.D., Managing Partner of Scrub Capital. “We are excited to support the team at Posterity Health as they promote digital, evidence-based male programs.”
The new funding will enable Posterity Health to scale its platform and expand its reach, working to ensure comprehensive reproductive care is accessible to men at every stage of life.
